115 related articles for article (PubMed ID: 12690929)
1. [Peroxisome proliferator activated receptors and cardiovascular disorders].
Norata GD; Pellegatta F; Catapano AL
Ital Heart J Suppl; 2003 Jan; 4(1):8-18. PubMed ID: 12690929
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Cabrero A; Cubero M; Llaverías G; Jové M; Planavila A; Alegret M; Sánchez R; Laguna JC; Carrera MV
Metabolism; 2003 May; 52(5):652-7. PubMed ID: 12759900
[TBL] [Abstract][Full Text] [Related]
3. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Curr Opin Pharmacol; 2005 Apr; 5(2):177-83. PubMed ID: 15780828
[TBL] [Abstract][Full Text] [Related]
4. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
Bełtowski J; Wójcicka G; Jamroz A
Postepy Hig Med Dosw; 2003; 57(2):199-217. PubMed ID: 12866356
[TBL] [Abstract][Full Text] [Related]
5. [Nonlipid effects of fibrates].
Celińska-Löwenhoff M; Undas A
Przegl Lek; 2004; 61(2):99-101. PubMed ID: 15230150
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.
Bouhlel MA; Staels B; Chinetti-Gbaguidi G
J Intern Med; 2008 Jan; 263(1):28-42. PubMed ID: 18042221
[TBL] [Abstract][Full Text] [Related]
8. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.
Smith AG; Muscat GE
Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648
[TBL] [Abstract][Full Text] [Related]
9. [Peroxisome proliferator activated receptors PPARs: their role in carbohydrate and lipid metabolism].
Andrééva-Gatéva P
Ann Biol Clin (Paris); 2003; 61(3):295-303. PubMed ID: 12805006
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
12. PPAR alpha, fibrates, lipid metabolism and inflammation.
Duval C; Fruchart JC; Staels B
Arch Mal Coeur Vaiss; 2004 Jun; 97(6):665-72. PubMed ID: 15283041
[TBL] [Abstract][Full Text] [Related]
13. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging.
Corti R; Osende JI; Fallon JT; Fuster V; Mizsei G; Jneid H; Wright SD; Chaplin WF; Badimon JJ
J Am Coll Cardiol; 2004 Feb; 43(3):464-73. PubMed ID: 15013132
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
Marx N; Duez H; Fruchart JC; Staels B
Circ Res; 2004 May; 94(9):1168-78. PubMed ID: 15142970
[TBL] [Abstract][Full Text] [Related]
15. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation.
Castrillo A; Tontonoz P
Annu Rev Cell Dev Biol; 2004; 20():455-80. PubMed ID: 15473848
[TBL] [Abstract][Full Text] [Related]
16. [Peroxisome proliferator-activated receptors and atherosclerosis].
Jin N; Wang X
Sheng Li Ke Xue Jin Zhan; 2004 Jan; 35(1):13-8. PubMed ID: 15127591
[TBL] [Abstract][Full Text] [Related]
17. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors and inflammation: take it to heart.
Smeets PJ; Planavila A; van der Vusse GJ; van Bilsen M
Acta Physiol (Oxf); 2007 Nov; 191(3):171-88. PubMed ID: 17935522
[TBL] [Abstract][Full Text] [Related]
19. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
20. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.
Kuwabara K; Murakami K; Todo M; Aoki T; Asaki T; Murai M; Yano J
J Pharmacol Exp Ther; 2004 Jun; 309(3):970-7. PubMed ID: 14982965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
